ACHV

2.36

1.67% -0.04

Pre-mercato: 2.38 0.02 +0.85%

Achieve Life Sciences Inc (ACHV)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ACHV Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.40

Aprire:

$2.39

Volume 24 ore:

262.01K

Relative Volume:

1.25

Capitalizzazione di mercato:

$78.04M

Reddito:

Utile/perdita netta:

$-32.94M

Rapporto P/E:

-2.1261

EPS:

-1.11

Flusso di cassa netto:

$-24.95M

1 W Prestazione:

+18.59%

1M Prestazione:

-17.48%

6M Prestazione:

-49.89%

1 anno Prestazione:

-48.42%

Intervallo 1D:

$2.36

$2.48

Intervallo di 1 settimana:

$1.96

$2.63

Portata 52W:

$1.84

$5.59

Achieve Life Sciences Inc Stock (ACHV) Company Profile

Nome

Achieve Life Sciences Inc

Settore

Healthcare (1155)

Industria

Biotechnology (677)

Telefono

425-686-1500

Indirizzo

22722 29TH DR. SE, SEATTLE, BC

Dipendente

Cinguettio

Prossima data di guadagno

2025-03-11

Ultimi documenti SEC

ACHV's Discussions on Twitter

Confronta ACHV con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ACHV Achieve Life Sciences Inc	2.36	78.04M	0	-32.94M	-24.95M	-1.11
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-14	Iniziato	Rodman & Renshaw	Buy
2024-09-27	Iniziato	Raymond James	Strong Buy
2023-05-10	Reiterato	Maxim Group	Buy
2021-06-23	Iniziato	Oppenheimer	Outperform

Achieve Life Sciences Inc Borsa (ACHV) Ultime notizie

Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025

Apr 23, 2025

Here are Rogue Funds Updates on Achieve Life Sciences (ACHV) - MSN

Apr 23, 2025

LPL Financial LLC Has $693,000 Stock Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World

Apr 23, 2025

Apr 22, 2025

Achieve Life Sciences announces publication of results from Phase 3 ORCA-3 trial - Yahoo Finance

Apr 22, 2025

Apr 21, 2025

Cytisinicline shows promise for smoking cessation By Investing.com - Investing.com South Africa

Apr 21, 2025

Achieve Life Sciences Expects to File New Drug Application in US for Smoking Cessation Medication - marketscreener.com

Apr 21, 2025

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine | ACHV Stock News - GuruFocus

Apr 21, 2025

Achieve Life Sciences (ACHV) Confirms Cytisinicline Efficacy in Phase 3 ORCA-3 Trial | ACHV Stock News - GuruFocus

Apr 21, 2025

Cytisinicline’s FDA Path Ignites ACHV Stock: Could This Biotech Gem Soar on Smoking and Vaping Cessation Breakthroughs? - Own Snap

Apr 21, 2025

Achieve Life Sciences Announces Cytisinicline Phase 3 - GlobeNewswire

Apr 21, 2025

Breakthrough Smoking Cessation Drug Outperforms Existing Treatments in Major Phase 3 Trial, JAMA Reports - Stock Titan

Apr 21, 2025

Apr 12, 2025

157,519 Shares in Achieve Life Sciences, Inc. (NASDAQ:ACHV) Purchased by Raymond James Financial Inc. - MarketBeat

Apr 12, 2025

Apr 08, 2025

Raymond James Financial Inc. Invests $554,000 in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World

Apr 08, 2025

Apr 01, 2025

ACHV Stock Touches 52-Week Low at $2.5 Amid Market Challenges - Investing.com UK

Apr 01, 2025

Mar 31, 2025

ACHIEVE LIFE SCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus

Mar 31, 2025

Mar 24, 2025

Contrasting Achieve Life Sciences (NASDAQ:ACHV) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Mar 24, 2025

Mar 23, 2025

Achieve Life Sciences (ACHV) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Mar 23, 2025

Mar 21, 2025

Insider Buying: Mark Oki Acquires Shares of Achieve Life Sciences Inc (ACHV) - GuruFocus

Mar 21, 2025

Mar 20, 2025